The biotechnology sector has had some ups and downs in recent years, to put it mildly. After a strong start in the first quarter of 2015, when 62 transactions were recorded, deal volume slowed considerably, to only 20 deals in the fourth quarter of 2015. One of the strongest headwinds has been the criticism of the pharmaceutical industry for the high prices charged for certain drugs. Presidential candidates and federal legislators have called for hearings on this issue, which caused some investors to pull back in this and the pharmaceutical sector.
